Article
p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer.
Pharmacogenetics - 1 Dec 1998
Przygodzki R M, Bennett W P, Guinee D G, Khan M A, Freedman A, Shields P G, Travis W D, Jett J R, Tazelaar H, Pairolero P, Trastek V, Liotta L A, Harris C C, Caporaso N E
Abstract excerpt
p53 mutation status was analysed in relation to DNA polymorphisms of GSTM1, CYP1A1 and CYP2E1 from 105 surgically resected non-small cell lung cancer cases. Demographic factors, smoking, occupation, family history, tumour histology, grade and stage were taken into account. p53 mutations, detected either directly by DNA sequencing (P = 0.04, adjusted for smoking) or indirectly by immunostaining (P = 0.06), were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.